JP2022516964A - ガンマデルタt細胞を調節するためのヘテロ二量体タンパク質 - Google Patents
ガンマデルタt細胞を調節するためのヘテロ二量体タンパク質 Download PDFInfo
- Publication number
- JP2022516964A JP2022516964A JP2021539876A JP2021539876A JP2022516964A JP 2022516964 A JP2022516964 A JP 2022516964A JP 2021539876 A JP2021539876 A JP 2021539876A JP 2021539876 A JP2021539876 A JP 2021539876A JP 2022516964 A JP2022516964 A JP 2022516964A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- seq
- domain
- cancer
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789344P | 2019-01-07 | 2019-01-07 | |
| US62/789,344 | 2019-01-07 | ||
| US201962876346P | 2019-07-19 | 2019-07-19 | |
| US62/876,346 | 2019-07-19 | ||
| US201962941176P | 2019-11-27 | 2019-11-27 | |
| US62/941,176 | 2019-11-27 | ||
| PCT/US2020/012589 WO2020146393A1 (en) | 2019-01-07 | 2020-01-07 | Heterodimeric proteins for modulating gamma delta t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516964A true JP2022516964A (ja) | 2022-03-03 |
| JP2022516964A5 JP2022516964A5 (cg-RX-API-DMAC7.html) | 2023-01-20 |
Family
ID=71521410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539876A Pending JP2022516964A (ja) | 2019-01-07 | 2020-01-07 | ガンマデルタt細胞を調節するためのヘテロ二量体タンパク質 |
Country Status (13)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566650A (zh) | 2018-06-21 | 2021-03-26 | 沙塔克实验室有限公司 | 异二聚体蛋白及其用途 |
| BR112021013193A2 (pt) * | 2019-01-07 | 2021-09-28 | Shattuck Labs, Inc. | Proteínas heterodiméricas para modulação de células t gama delta |
| WO2022093310A1 (en) * | 2020-10-26 | 2022-05-05 | Shattuck Labs, Inc. | Homodimeric and heterodimeric proteins comprising butyrophilin |
| EP4247409A4 (en) * | 2020-11-19 | 2024-11-13 | Shattuck Labs, Inc. | Methods of identifying gamma delta t cell-modulating agents |
| US20240076346A1 (en) * | 2021-01-13 | 2024-03-07 | Kahr Medical Ltd. | Type i membrane proteins heterodimers and methods of use thereof |
| US20240082306A1 (en) * | 2021-02-03 | 2024-03-14 | Bioheng Therapeutics Limited | Novel chimeric antigen receptor and use thereof |
| JP2024511992A (ja) * | 2021-03-16 | 2024-03-18 | シャタック ラボ,インコーポレイテッド | ガンマデルタt細胞刺激 |
| WO2023102617A1 (en) * | 2021-12-09 | 2023-06-15 | The University Of Melbourne | Modified butyrophilin and butyrophilin complexes |
| WO2023154812A1 (en) * | 2022-02-09 | 2023-08-17 | Shattuck Labs, Inc. | Multispecific heterodimeric proteins |
| WO2024006907A2 (en) * | 2022-06-29 | 2024-01-04 | Shattuck Labs, Inc. | B7h3-targeted gamma delta t cell modulation |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| WO2024191989A1 (en) * | 2023-03-14 | 2024-09-19 | Shattuck Labs, Inc. | Treatment of b cell-mediated diseases by activating cd20-targeted gamma delta t cells |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016191305A1 (en) * | 2015-05-22 | 2016-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| US20180064787A1 (en) * | 2015-10-01 | 2018-03-08 | Heat Biologics, Inc. | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| WO2018082590A1 (zh) * | 2016-11-02 | 2018-05-11 | 北京蛋白质组研究中心 | 肿瘤免疫治疗靶标及其应用 |
| US20180296636A1 (en) * | 2014-11-25 | 2018-10-18 | Albert Einstein College Of Medicine, Inc. | Btnl9 and ermap as novel inhibitors of the immune system for immunotherapies |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060264360A1 (en) | 2002-04-12 | 2006-11-23 | Yale University Office Of Cooperstive Research | Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4 |
| US20040053307A1 (en) | 2002-06-17 | 2004-03-18 | Wyeth | Inhibition of T cell activation by butyrophilin 4 and B7-L1 |
| AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| EP1702622A1 (en) | 2005-03-18 | 2006-09-20 | CONARIS research institute AG | Soluble BTNL2 protein useful to inhibit inflammatory disorders |
| DK1999154T3 (da) * | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2008154516A2 (en) | 2007-06-11 | 2008-12-18 | The Board Of Regents, The Universtity Ot Texas System | Btnl2 fusion protein for t-cell activity modulation |
| GB0717101D0 (en) | 2007-09-03 | 2007-10-10 | Cambridge Entpr Ltd | Tumour marker |
| EP3663318A1 (en) * | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2011127418A1 (en) | 2010-04-09 | 2011-10-13 | Amgen Inc. | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
| WO2011133886A2 (en) * | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| IN2014CN03887A (cg-RX-API-DMAC7.html) * | 2011-10-27 | 2015-10-16 | Genmab As | |
| US10131709B2 (en) | 2011-12-28 | 2018-11-20 | Immunoqure Ag | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 |
| HUE037186T2 (hu) | 2011-12-28 | 2018-08-28 | Immunoqure Ag | Eljárás humán antitestek izolálására |
| US20150166630A1 (en) | 2012-07-19 | 2015-06-18 | Amgen Inc. | Btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| EP2941438A1 (en) | 2013-01-01 | 2015-11-11 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| GB201300049D0 (en) | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-stimulatory dendritic cells |
| GB201300052D0 (en) | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-suppressive dendritic cells |
| CN110724193B (zh) | 2013-07-03 | 2023-05-05 | 因美诺克股份公司 | 人单克隆抗il-32抗体、多核苷酸、载体、宿主细胞、制备方法、组合物及应用 |
| WO2015001047A1 (en) | 2013-07-03 | 2015-01-08 | Immunoqure Ag | Method of providing anti-human cytokine antibodies for pharmaceutical use |
| CA2917112C (en) | 2013-07-03 | 2022-07-05 | Immunoqure Ag | Human anti-ifn-alpha antibodies |
| US20160376364A1 (en) | 2013-11-29 | 2016-12-29 | Csl Limited | Method of treating cancer |
| EP3087099A4 (en) * | 2013-12-23 | 2017-07-19 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| CN108473958A (zh) | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| KR102803158B1 (ko) | 2015-12-02 | 2025-05-08 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도 |
| GB201521389D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| CN109071632B (zh) * | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| EP3436475A1 (en) | 2016-03-29 | 2019-02-06 | STCube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
| WO2018201130A1 (en) | 2017-04-28 | 2018-11-01 | The Brigham And Women's Hospital, Inc. | Targeting gamma-delta t cells in obesity and cachexia |
| CN111148762A (zh) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途 |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| EP4467146A3 (en) | 2017-09-15 | 2025-05-07 | King's College London | Compositions and methods for enhancing gamma delta t cells in the gut |
| KR102764182B1 (ko) | 2017-09-21 | 2025-02-07 | 임체크 테라퓨틱스 | Btn2에 대해 특이성을 갖는 항체 및 이의 용도 |
| BR112021013193A2 (pt) * | 2019-01-07 | 2021-09-28 | Shattuck Labs, Inc. | Proteínas heterodiméricas para modulação de células t gama delta |
-
2020
- 2020-01-07 BR BR112021013193-0A patent/BR112021013193A2/pt unknown
- 2020-01-07 KR KR1020217023232A patent/KR20210113244A/ko not_active Ceased
- 2020-01-07 WO PCT/US2020/012589 patent/WO2020146393A1/en not_active Ceased
- 2020-01-07 CN CN202080009216.8A patent/CN113329759A/zh active Pending
- 2020-01-07 CA CA3125474A patent/CA3125474A1/en active Pending
- 2020-01-07 MX MX2021008022A patent/MX2021008022A/es unknown
- 2020-01-07 JP JP2021539876A patent/JP2022516964A/ja active Pending
- 2020-01-07 EP EP20738523.8A patent/EP3902557A4/en not_active Withdrawn
- 2020-01-07 PH PH1/2021/551475A patent/PH12021551475A1/en unknown
- 2020-01-07 AU AU2020205965A patent/AU2020205965A1/en not_active Abandoned
- 2020-01-07 SG SG11202106895UA patent/SG11202106895UA/en unknown
- 2020-01-13 US US16/741,146 patent/US11098093B2/en active Active
- 2020-06-03 US US16/891,672 patent/US10988517B2/en active Active
-
2021
- 2021-07-06 IL IL284658A patent/IL284658A/en unknown
- 2021-07-16 US US17/378,110 patent/US20220025000A1/en not_active Abandoned
-
2022
- 2022-06-01 US US17/829,778 patent/US11643447B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180296636A1 (en) * | 2014-11-25 | 2018-10-18 | Albert Einstein College Of Medicine, Inc. | Btnl9 and ermap as novel inhibitors of the immune system for immunotherapies |
| WO2016191305A1 (en) * | 2015-05-22 | 2016-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| US20180064787A1 (en) * | 2015-10-01 | 2018-03-08 | Heat Biologics, Inc. | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| WO2018082590A1 (zh) * | 2016-11-02 | 2018-05-11 | 北京蛋白质组研究中心 | 肿瘤免疫治疗靶标及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| FRONTIERS IN IMMUNOLOGY, vol. 9, JPN6023048559, 2018, pages 1601, ISSN: 0005333155 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL284658A (en) | 2021-08-31 |
| US11098093B2 (en) | 2021-08-24 |
| US20200308238A1 (en) | 2020-10-01 |
| EP3902557A4 (en) | 2023-06-07 |
| US20220025000A1 (en) | 2022-01-27 |
| PH12021551475A1 (en) | 2022-05-02 |
| MX2021008022A (es) | 2021-08-05 |
| US11643447B2 (en) | 2023-05-09 |
| WO2020146393A1 (en) | 2020-07-16 |
| AU2020205965A1 (en) | 2021-07-01 |
| SG11202106895UA (en) | 2021-07-29 |
| CN113329759A (zh) | 2021-08-31 |
| EP3902557A1 (en) | 2021-11-03 |
| KR20210113244A (ko) | 2021-09-15 |
| US20230020258A1 (en) | 2023-01-19 |
| BR112021013193A2 (pt) | 2021-09-28 |
| US20200216505A1 (en) | 2020-07-09 |
| US10988517B2 (en) | 2021-04-27 |
| CA3125474A1 (en) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11643447B2 (en) | Heterodimeric proteins for modulating gamma delta T cells | |
| JP7303254B2 (ja) | I型及びii型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 | |
| JP7260477B2 (ja) | Tigit及びlightベースのキメラタンパク質 | |
| US20230416333A1 (en) | Homodimeric and heterodimeric proteins comprising butyrophilin | |
| US20230408523A1 (en) | Methods of identifying gamma delta t cell-modulating agents | |
| JP2024511992A (ja) | ガンマデルタt細胞刺激 | |
| RU2775490C2 (ru) | Химерные белки на основе tigit и light | |
| HK40092182A (en) | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins | |
| HK40091905A (en) | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins | |
| CN117120073A (zh) | 鉴定γ/δT细胞调节剂的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240328 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240816 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250107 |